444 related articles for article (PubMed ID: 32340618)
21. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
[TBL] [Abstract][Full Text] [Related]
22. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
[TBL] [Abstract][Full Text] [Related]
23. Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer's disease dementia: a systematic review.
Grueso S; Viejo-Sobera R
Alzheimers Res Ther; 2021 Sep; 13(1):162. PubMed ID: 34583745
[TBL] [Abstract][Full Text] [Related]
24. Magnetic Resonance Texture Analysis in Alzheimer's disease.
Cai JH; He Y; Zhong XL; Lei H; Wang F; Luo GH; Zhao H; Liu JC
Acad Radiol; 2020 Dec; 27(12):1774-1783. PubMed ID: 32057617
[TBL] [Abstract][Full Text] [Related]
25. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.
Lista S; Garaci FG; Ewers M; Teipel S; Zetterberg H; Blennow K; Hampel H
Alzheimers Dement; 2014 May; 10(3):381-92. PubMed ID: 23850330
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's disease neuroimaging.
Whitwell JL
Curr Opin Neurol; 2018 Aug; 31(4):396-404. PubMed ID: 29762152
[TBL] [Abstract][Full Text] [Related]
27. Neuroimaging in dementias.
de Souza LC; Lehéricy S; Dubois B; Stella F; Sarazin M
Curr Opin Psychiatry; 2012 Nov; 25(6):473-9. PubMed ID: 23037962
[TBL] [Abstract][Full Text] [Related]
28. Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia.
Ricci M; Cimini A; Chiaravalloti A; Filippi L; Schillaci O
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050556
[TBL] [Abstract][Full Text] [Related]
29. Improving PET Imaging Acquisition and Analysis With Machine Learning: A Narrative Review With Focus on Alzheimer's Disease and Oncology.
Duffy IR; Boyle AJ; Vasdev N
Mol Imaging; 2019; 18():1536012119869070. PubMed ID: 31429375
[TBL] [Abstract][Full Text] [Related]
30. Neurological update: neuroimaging in dementia.
Rittman T
J Neurol; 2020 Nov; 267(11):3429-3435. PubMed ID: 32638104
[TBL] [Abstract][Full Text] [Related]
31. Alzheimer's disease diagnosis framework from incomplete multimodal data using convolutional neural networks.
Abdelaziz M; Wang T; Elazab A
J Biomed Inform; 2021 Sep; 121():103863. PubMed ID: 34229061
[TBL] [Abstract][Full Text] [Related]
32. Imaging Methods Applicable in the Diagnostics of Alzheimer's Disease, Considering the Involvement of Insulin Resistance.
Hnilicova P; Kantorova E; Sutovsky S; Grofik M; Zelenak K; Kurca E; Zilka N; Parvanovova P; Kolisek M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834741
[TBL] [Abstract][Full Text] [Related]
33. Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography.
Tripathi SM; Murray AD
Neuroscientist; 2022 Oct; 28(5):507-519. PubMed ID: 33660556
[TBL] [Abstract][Full Text] [Related]
34. A literature review of MRI techniques used to detect amyloid-beta plaques in Alzheimer's disease patients.
Yu B; Shan Y; Ding J
Ann Palliat Med; 2021 Sep; 10(9):10062-10074. PubMed ID: 34551578
[TBL] [Abstract][Full Text] [Related]
35. Disturbances in brain energy metabolism in insulin resistance and diabetes and Alzheimer's disease - Learnings from brain imaging biomarkers.
Heurling K; Johansson E; Leuzy A
Int Rev Neurobiol; 2020; 154():111-130. PubMed ID: 32739001
[TBL] [Abstract][Full Text] [Related]
36. University College London/University of Gothenburg PhD course "Biomarkers in neurodegenerative diseases" 2019-course organisation.
Khatun A; Paterson RW; Schöll M
Alzheimers Res Ther; 2020 Feb; 12(1):18. PubMed ID: 32019594
[TBL] [Abstract][Full Text] [Related]
37. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523
[TBL] [Abstract][Full Text] [Related]
38. [Biomarkers for early diagnosis of Alzheimer's disease].
Frederiksen KS; Hasselbalch S; Law I; Højgaard L; Waldemar G
Ugeskr Laeger; 2015 Jun; 177(24):. PubMed ID: 26058526
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances in Neuroimaging Techniques to Assist Clinical Trials on Cell-Based Therapies in Neurodegenerative Diseases.
Wilson H; de Natale ER; Politis M
Stem Cells; 2022 Aug; 40(8):724-735. PubMed ID: 35671344
[TBL] [Abstract][Full Text] [Related]
40. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.
Hall B; Mak E; Cervenka S; Aigbirhio FI; Rowe JB; O'Brien JT
Ageing Res Rev; 2017 Jul; 36():50-63. PubMed ID: 28315409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
